Photodynamic therapy mediated by a selective nanoemulsion for breast cancer treatment: in vitro and in vivo evaluation
AlClPc-PDT significantly suppressed tumor progression, reducing the tumor mass by approximately 50%.
In this study, we investigated the tumor-accumulating efficacy of photodynamic therapy (PDT) mediated by an aluminum chloride phthalocyanine-loaded nanoemulsion (AlClPc-NE) against breast cancer (MCF-7 and MDA-MB-231) and non-tumorigenic (MCF-10A) cell lines. The optimized AlClPc-NE formulation exhibited a mean hydrodynamic diameter of 168 nm, zeta potential of – 29 mV, low polydispersity (0.25), encapsulation efficiency of 81.10%, and estimated stability of 12 months. The system effectively preserved the drug photoactivity, achieving a robust singlet oxygen quantum yield (ΦΔ = 0.52). In vitro assays confirmed excellent dark biocompatibility of the nanocomposites. Upon irradiation, AlClPc-PDT exhibited potent phototoxicity. Crucially, a selective therapeutic window was observed 24 h post-treatment at a light density of 1000 mJ/cm2, significantly reducing tumor cell viability by over 50% while preserving non-tumorigenic MCF-10A cells. Translating these findings to an in vivo orthotopic breast cancer model, AlClPc-PDT significantly suppressed tumor progression, reducing the tumor mass by approximately 50%. The AlClPc-NE platform emerged as a highly localized therapeutic strategy, prioritizing tumor eradication while limiting potential side effects in healthy tissues.
The study demonstrates that a nanoemulsion‑encapsulated photosensitizer can achieve selective photodynamic therapy against breast cancer cells in vitro and in vivo, sparing normal cells and reducing tumor burden by half, which supports further development of this targeted nanomedicine platform.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC